Abstract
Get full access to this article
View all access options for this article.
References
1.
Gilman
AG
Goodman
LS
Rall
TW
Murad
F
, eds. Goodman and Gilman's the pharmacological basis of therapeutics . 7th ed . New York : Macmillan , 1985 : 1694 .
2.
Edwards
DJ
Svensson
CK
Visco
JP
Lalka
D
. Clinical pharmacokinetics of pethidine: 1982 . Clin Pharmacokinet
1982 ; 7 : 421 –33 .
3.
Mather
LE
Meffin
PJ
. Clinical pharmacokinetics of pethidine . Clin Pharmacokinet
1978 ; 3 : 352 –68 .
4.
Mauro
VF
Bonfiglio
MF
Spunt
AL
. Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia . Clin Pharm
1986 ; 5 : 837 –9 .
5.
Armstrong
PJ
Bonsten
A
. Normeperidine toxicity . Anesth Analg
1986 ; 65 : 536 –8 .
6.
Goetting
MG
Thirman
MJ
. Neurotoxicity of meperidine . Ann Emerg Med
1985 ; 14 : 1007 –9 .
7.
Szeto
HH
Inturrisi
CE
Houde
R
Saal
S
Cheigh
J
Reidenberg
MM
. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer . Ann Intern Med
1977 ; 86 : 738 –41 .
8.
Kaiko
RF
Foley
KM
Grabinski
PY
Central nervous system excitatory effects of meperidine in cancer patients . Ann Neurol
1983 ; 13 : 180 –5 .
9.
Verbeeck
RK
Branch
RA
Wilkinson
GR
. Meperidine disposition in man: Influence of urinary pH and route of administration . Clin Pharmacol Ther
1981 ; 30 : 619 –28 .